Skip To Main Content
Jalal Baranseh on Muck Rack

Jalal Baranseh

As seen in: UroToday
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jalal

Contact Jalal, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

De-Escalation Therapy in Metastatic Prostate Cancer: A Retrospective Study on Intermittent ADT and ARPI Combination Treatment.

|
By Tomer Charas, Barak Talmor, Jalal Baranseh
| UroToday Verified
Androgen deprivation therapy (ADT) combined with an androgen receptor pathway inhibitor (ARPI) is standard care for metastatic prostate cancer (mPCa), but prolonged treatment causes clinical and financial toxicity. The efficacy of intermittent treatment in the ARPI era remains unclear. We evaluated outcomes after planned treatment cessation following a deep response to ADT plus ARPI.
Open in Who Shared Issue with article?
See all 1 articles